Trial
NCT03548246
Androgen Reduction in Congenital Adrenal Hyperplasia
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Texas Southwestern Medical Center
Collaborators
National Institutes of Health Clinical Center (CC); University of Michigan; Children's Hospital Los Angeles; Feinstein Institute for Medical Research
Condition
Congenital Adrenal Hyperplasia
Intervention
Abiraterone acetate
Why stopped
This study plan has halted and was withdrawn from the IRB.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-02-01